Actions

Newsfeed Popular Local Discover Follows Blocks Bookmarks Filters Settings PowerUps Help Updates

prnewswire.com / Share Newsitem

View, share or embed this newsitem using the details below.

PR Newswire: press release distribution, targeting, monitoring and marketing

Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non

TOKYO, PRINCETON, N.J. and CAMBRIDGE, Mass., Jan. 28, 2025 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., announced today the REZILIENT1 trial, a Phase 1/2 clinical trial of zipalertinib

https://newsreadery.com/go/c312485dabe745e0ac63ce21f7e8e50c

Save

Back

Read Full Article